TG Therapeutics Stock Surges After Drug Trial Updatebenzinga.comShares of TG Therapeutics Inc (
NASDAQ: TGTX) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million Morefool.comVericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Positionfool.comThis clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drugfool.comAlumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investmentfool.comViking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Dropfool.comThis biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Soleus Adds a Significant Number of Celcuity Sharesfool.comThis clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'stocktwits.comTG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Sharesfool.comThis commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter?stocktwits.comOn Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026stocktwits.comThe company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.
